On April 26, 2023 Novartis reported that it will present new data from its oncology portfolio at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, including advancements in breast cancer, prostate cancer and lung cancer from more than 40 Novartis-sponsored and investigator-led trials (Press release, Novartis, APR 26, 2023, View Source [SID1234630554]). Primary results from the NATALEE trial evaluating Kisqali (ribociclib) plus endocrine therapy in patients with stage II and stage III hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer at risk of cancer recurrence, regardless of nodal involvement, will be presented.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We look forward to sharing the primary analysis from the Phase III NATALEE trial of Kisqali in the investigational setting in a broad population of patients with early-stage breast cancer at ASCO (Free ASCO Whitepaper)," said Shreeram Aradhye, M.D., President, Global Drug Development and Chief Medical Officer, Novartis. "These promising data, together with other key updates, illustrate how we continue to advance our pipeline in oncology, with the potential to help address the significant unmet needs of patients living with cancer."

Key highlights of data accepted by ASCO (Free ASCO Whitepaper) include:

Medicine  Abstract Title  Abstract Number/ Presentation Details  
Kisqali (ribociclib)* 

Phase III NATALEE trial of ribociclib + endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer

Abstract #LBA500
Oral presentation:
Friday, June 2, 2:45 – 5:45pm CDT
Kisqali (ribociclib)*  Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2- advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial

Abstract #1063
Poster available:
Sunday, June 4, 8:00 – 11:00am CDT
Kisqali (ribociclib)* 

Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-Enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study. HARMONIA SOLTI-2101 / AFT-58

Abstract #TPS1125
Poster available:
Sunday, June 4, 8:00 – 11:00am CDT
Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

Building a predictive model for outcomes with [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer using VISION data: Preliminary results

Abstract #5028
Poster available:
Saturday, June 3, 8:00 – 11:00am CDT
Pluvicto (lutetium Lu 177 vipivotide tetraxetan) Tumor dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study

Abstract #5046
Poster available:
Saturday, June 3, 8:00 – 11:00am CDT
JDQ443 KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C-mutated solid tumors including non-small cell lung cancer (NSCLC)

Abstract #9007
Oral presentation:
Tuesday, June 6, 9:45am – 12:45pm CDT

 
PHE885 Updated phase I study results of PHE885, a T-Charge manufactured BCMA-directed CAR-T cell therapy, for patients (pts) with r/r multiple myeloma (RRMM) Abstract #8004
Oral presentation:
Saturday, June 3, 1:15 – 4:15pm CDT
Product Information
For full prescribing information, including approved indications and important safety information about marketed products, please visit View Source